- Home
- OXM vs MNPR Comparison
OXM vs MNPR Comparison
Compare OXM & MNPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OXM | MNPR |
|---|---|---|
| Founded | 1942 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 603.5M | 531.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | OXM | MNPR |
|---|---|---|
| Price | $34.24 | $65.50 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 13 |
| Target Price | $43.60 | ★ $97.83 |
| AVG Volume (30 Days) | ★ 685.6K | 263.6K |
| Earning Date | 12-10-2025 | 11-13-2025 |
| Dividend Yield | ★ 8.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,493,854,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.61 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $30.57 | $21.00 |
| 52 Week High | $89.86 | $105.00 |
Technical Indicators
Market Signals| Indicator | OXM | MNPR |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 34.74 |
| Support Level | $35.76 | $64.25 |
| Resistance Level | $37.99 | $74.34 |
| Average True Range (ATR) | 1.83 | 4.26 |
| MACD | -0.37 | -0.59 |
| Stochastic Oscillator | 42.25 | 8.18 |
Price Performance
Historical ComparisonAbout OXM Oxford Industries Inc.
Oxford Industries Inc is an apparel manufacturing company that designs, sources, markets, and distributes products under the brand name Tommy Bahama, and Lilly Pulitzer. Tommy Bahama designs, sources, markets, and distributes men's and women's sportswear and related products. Lilly Pulitzer designs, sources, markets, and distributes upscale collections of women's and women's dresses, sportswear, and related products. The company generates majority of its revenue from the Tommy Bahama division.
About MNPR Monopar Therapeutics Inc.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.